Elizabeth J Davis, M.D.

Assistant Professor

Faculty Appointments
Assistant Professor of Medicine
M.D., Wright State University, Dayton, OhioB.S., Biology, Duke University, Durham, North Carolina
Office Address
C409 Med Inn Bldg
1500 E. Medical Center Drive SPC5843
Ann Arbor, MI 48109
Clinical Research Keywords
soft tissue sarcoma, bone sarcoma, GIST
Davis EJ, Perez MC, Ayoubi N, Zhao S, Ye F, Wang DY, Sosman JA, Al-Rohil RN, Eroglu Z, Johnson DB. Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. J. Immunother [print-electronic]. 2019 Mar 3/13/2019; PMID: 30882548, DOI: 10.1097/CJI.0000000000000258, ISSN: 1537-4513.

Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB. Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist [print-electronic]. 2019 Feb 2/28/2019; PMID: 30819785, PII: theoncologist.2018-0574, DOI: 10.1634/theoncologist.2018-0574, ISSN: 1549-490X.

Davis EJ, Johnson DB. Targeting tissue factor in advanced solid tumours. Lancet Oncol [print-electronic]. 2019 Feb 2/7/2019; PMID: 30745091, PII: S1470-2045(18)30912-4, DOI: 10.1016/S1470-2045(18)30912-4, ISSN: 1474-5488.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Dec 12/1/2018; 4(12): 1721-8. PMID: 30242316, PII: 2701721, DOI: 10.1001/jamaoncol.2018.3923, ISSN: 2374-2445.

Pender A, Davis EJ, Chauhan D, Messiou C, Al-Muderis O, Thway K, Fisher C, Zaidi S, Miah A, Judson I, van der Graaf W, Keedy VL, Benson C, Jones RL. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med. Oncol. 2018 Aug 8/20/2018; 35(10): 131. PMID: 30128716, PMCID: PMC6105245, PII: 10.1007/s12032-018-1193-5, DOI: 10.1007/s12032-018-1193-5, ISSN: 1559-131X.

Davis EJ, Johnson DB, Sosman JA, Chandra S. Melanoma: What do all the mutations mean?. Cancer [print-electronic]. 2018 Apr 4/17/2018; PMID: 29663336, DOI: 10.1002/cncr.31345, ISSN: 1097-0142.

Wang DY, Johnson DB, Davis EJ. Toxicities Associated With PD-1/PD-L1 Blockade. Cancer J. 2017 Dec; 24(1): 36-40. PMID: 29360726, PII: 00130404-201801000-00007, DOI: 10.1097/PPO.0000000000000296, ISSN: 1540-336X.

Davis EJ, Johnson DB. Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing. Per Med [print-electronic]. 2017 May; 14(3): 189-92. PMID: 28861116, PMCID: PMC5573119, DOI: 10.2217/pme-2017-0014, ISSN: 1741-0541.

Davis EJ, Wu YM, Robinson D, Schuetze SM, Baker LH, Athanikar J, Cao X, Kunju LP, Chinnaiyan AM, Chugh R. Next generation sequencing of extraskeletal myxoid chondrosarcoma. Oncotarget. 2017 Mar 3/28/2017; 8(13): 21770-7. PMID: 28423517, PII: 15568, DOI: 10.18632/oncotarget.15568, ISSN: 1949-2553.

Davis EJ, Chugh R. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy. Drug Des Devel Ther. 2017; 11: 3579-87. PMID: 29263653, PMCID: PMC5732568, PII: dddt-11-3579, DOI: 10.2147/DDDT.S121298, ISSN: 1177-8881.

Davis EJ, Zhao L, Lucas DR, Schuetze SM, Baker LH, Zalupski MM, Thomas D, Chugh R. SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy. BMC Cancer. 2016; 16: 663. PMID: 27544129, PMCID: PMC4992190, PII: 10.1186/s12885-016-2694-2, DOI: 10.1186/s12885-016-2694-2, ISSN: 1471-2407.

Davis EJ, Griffith KA, Kim EJ, Ruch JM, McDonnell KJ, Zalupski MM. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am. J. Clin. Oncol [print-electronic]. 2015 Nov 11/3/2015; PMID: 26535993, PMCID: PMC4854803, DOI: 10.1097/COC.0000000000000240, ISSN: 1537-453X.

Davis EJ, Chugh R, Zhao L, Lucas DR, Biermann JS, Zalupski MM, Feng M, Wong SL, Jacobson J, Zyczynski L, Reinke D, Metko G, Baker LH, Schuetze SM. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. Eur. J. Cancer [print-electronic]. 2015 Sep; 51(13): 1794-802. PMID: 26066736, PII: S0959-8049(15)00441-4, DOI: 10.1016/j.ejca.2015.05.010, ISSN: 1879-0852.

Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, Schuetze SM. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann. Oncol [print-electronic]. 2015 Jul; 26(7): 1459-64. PMID: 25858498, PMCID: PMC4478972, PII: mdv171, DOI: 10.1093/annonc/mdv171, ISSN: 1569-8041.

Alva A, Davis E, Chinnaiyan AM, Dhanasekaran S, Mehra R. Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia. Urol Case Rep. 2015 Jul; 3(4): 98-100. PMID: 26793516, PMCID: PMC4672646, PII: S2214-4420(15)00008-X, DOI: 10.1016/j.eucr.2015.01.007, ISSN: 2214-4420.

Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA. Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. Cancer [print-electronic]. 2014 Sep 9/1/2014; 120(17): 2735-41. PMID: 24842808, PMCID: PMC4195444, DOI: 10.1002/cncr.28769, ISSN: 1097-0142.

Oroszi G, Lapteva L, Davis E, Yarboro CH, Weickert T, Roebuck-Spencer T, Bleiberg J, Rosenstein D, Pao M, Lipsky PE, Goldman D, Lipsky RH, Illei GG. The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus. Ann. Rheum. Dis [print-electronic]. 2006 Oct; 65(10): 1330-5. PMID: 16606648, PMCID: PMC1798324, PII: ard.2006.051623, DOI: 10.1136/ard.2006.051623, ISSN: 0003-4967.